GlassScriptPhysician profile
Elizabeth K Mize
NPI 1013271428
$2,705.24
in general payments reported to CMS, 2019-2025
26 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $192 · 2021: $416 · 2022: $342 · 2023: $358 · 2024: $601 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.99 | 2019-2025 | |
| Astellas Pharma US INC | $280.62 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $273.93 | 2019-2025 | |
| Exeltis, USA INC. | $186.75 | 2020-2025 | Slynd |
| Integra Lifesciences Corporation | $161.54 | 2024 | Tenoglide |
| Biogen, INC. | $150.06 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $133.32 | 2021 | |
| Daiichi Sankyo INC. | $108.54 | 2019-2024 | Injectafer |
| Pfizer INC. | $97.20 | 2019-2025 | |
| Organon LLC | $90.46 | 2022-2025 | Nexplanon, Jada System |
| Hologic Sales and Service, LLC | $80.10 | 2022-2024 | Acessa Provu System, Omni Hysteroscope, Novasure |
| Mayne Pharma Commercial LLC | $64.79 | 2021-2025 | |
| Therapeuticsmd, INC. | $62.12 | 2020-2022 | |
| Dexcom, INC. | $54.48 | 2025 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $52.51 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $44.06 | 2019 | |
| Boston Scientific Corporation | $35.01 | 2024 | Advantage System |
| Avanos Medical | $31.06 | 2019 | |
| Merck Sharp & Dohme LLC | $26.34 | 2019 | |
| Duchesnay USA Incorporated | $23.76 | 2019 | |
| Allergan, INC. | $23.40 | 2019 | |
| Convatec INC. | $22.25 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2024 | Trintellix |
| Acella Pharmaceuticals, LLC | $15.38 | 2025 | NP Thyroid 60 |
| Millicent US INC | $14.51 | 2025 | Intrarosa, Femring |
| Coopersurgical, INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.